Initial Approval: January 10, 2018

## **CRITERIA FOR PRIOR AUTHORIZATION**

Trelegy Ellipta® (Fluticasone/Umeclidinium/Vilanterol)

PROVIDER GROUP Pharmacy

**MANUAL GUIDELINES** The following drug requires prior authorization:

Trelegy Ellipta® (Fluticasone/Umeclidinium/Vilanterol)

## **CRITERIA FOR APPROVAL** (must meet all of the following):

- Patient must have a diagnosis of chronic obstructive pulmonary disease (COPD)
- Must meet one of the following:

**LENGTH OF APPROVAL:** 12 months

- Patient is currently on a fixed-dose combination of fluticasone and vilanterol for airflow obstruction and reducing exacerbations and require additional therapy
- o Patient is currently receiving umeclidinium and a fixed-dose combination of fluticasone and vilanterol
- Patient must be 18 years of age or older
- Dose must not exceed one inhalation per day

Drug Utilization Review Committee Chair	PHARMACY PROGRAM MANAGER
	DIVISION OF HEALTH CARE FINANCE
	KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT

Date Date